Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - Boston Scientific (NYSE:BSX)

This health care stock forming a 'big base breakout' is ready to separate from the pack, charts indicate

David Keller breaks down the charts in Boston Scientific.

Boston Scientific halves expected tariff hit

The company now expects a tariff charge of $100 million this year, down from a $200 million impact forecast on the company’s first-quarter earnings call.

Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - Boston Scientific (NYSE:BSX)

Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation‘s (NYSE:BSX) momentum—and hint at where its next product wins may come. Boston Scientific on Wednesday reported second-quarter 2025 revenues of $5.06 billion, beating the consensus estimate of $4.89 billion. “This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment…

Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise

Boston Scientific has raised its 2025 profit outlook to between $2.95 and $2.99 per share amid strong Q2 performance in its cardiovascular unit, driven in large part by the uptake of its Farapulse pulsed field ablation (PFA) system.The post Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise appeared first on Medical Device Network.